TradingView
MarketMoversReport
19 août 2022 17:00
Axsome Therapeutics Announces FDA Approval of AUVELITY™
Long
NASDAQ:AXSM
1D
Axsome Therapeutics, Inc.
NASDAQ
Description
⋅
19 août 2022 17:00
AXSM: Axsome Therapeutics, Inc.
2022-08-19 Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
Beyond Technical Analysis
Plus